Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus KURVELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus KURVELO.
ASHLYNA vs KURVELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
KURVELO (trofinetide) is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). It is thought to reduce neuroinflammation and normalize synaptic function by modulating the activity of microglia and astrocytes, and by enhancing the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
100 mg orally once daily
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is 12-15 hours; requires dose adjustment in renal impairment.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Primarily renal excretion (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Category C
Category C
Contraceptive
Contraceptive